Tag: KDC-MN-038

  • Nebracetam

    Phenyl-substituted aminomethyl pyrrolidinone

    A 4-phenyl-pyrrolidinone with M1 muscarinic receptor agonist activity developed by Daiichi for cognitive impairment, discontinued in development.

    Abstract

    Nebracetam (WEB-1881-FU; 4-phenyl-2-pyrrolidinone-1-acetamide methyl derivative; CAS 97205-34-0; molecular formula C13H18N2O2; molecular weight 234.30) is a piracetam analog developed by Daiichi Pharmaceutical in Japan in the 1980s with structural features distinct from the classical racetam class. The compound includes a 4-phenyl group on the pyrrolidinone ring (similar to phenylpiracetam) and an aminomethyl modification on the acetamide side chain. Pharmacology shows partial M1 muscarinic acetylcholine receptor agonist activity in addition to the cholinergic facilitation typical of the racetam class. Phase 2 trials in mild cognitive impairment and elderly memory disorders showed positive but modest results; the development program was discontinued and the compound was never approved. The compound is sold as a research chemical in jurisdictions where it is not specifically scheduled. Pharmacokinetics include plasma half-life of approximately 4 hours and good oral bioavailability. The clinical evidence base is limited; the M1 muscarinic agonist activity introduces a distinct profile from the open-chain racetams.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.